

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities nor is it calculated to invite any such offer or invitation. In particular, this announcement does not constitute and is not an offer to sell or an invitation or a solicitation of any offer to buy or subscribe for any securities in Hong Kong, the United States of America or elsewhere. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities described herein have not been and will not be registered under the U.S. Securities Act and will be offered and sold (a) in the United States only to “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act), in reliance on Rule 144A under the U.S. Securities Act or another available exemption from the registration requirements of the U.S. Securities Act, and (b) outside the United States in offshore transactions in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur. There will be no public offering of securities in the United States of America or any jurisdiction other than India.

Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from the United States of America or any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

FOSUN PHARMA
复星医药

上海復星醫藥(集團)股份有限公司
Shanghai Fosun Pharmaceutical
(Group) Co., Ltd.*

*(a joint stock limited company incorporated in the People’s
Republic of China with limited liability)*

(Stock Code: 02196)

FOSUN 复星

復星國際有限公司
FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability)
(Stock Code: 00656)

JOINT ANNOUNCEMENT
UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING
OF GLAND PHARMA LIMITED ON BSE LIMITED AND
NATIONAL STOCK EXCHANGE
OF INDIA LIMITED

References are made to the announcements of Fosun Pharma dated 1 November 2019 and 11 May 2020, the joint announcement of Fosun Pharma and Fosun International dated 10 July 2020 (the “**Announcements**”) and the circular of Fosun Pharma dated 12 November 2019 (the “**Circular**”) in relation to the Proposed Spin-off and Separate Listing. Capitalised terms used in this announcement shall have the same meaning ascribed to them in the Announcements and Circular unless otherwise defined.

Fosun Pharma and Fosun International were notified that, on 31 October 2020, Gland Pharma filed the red herring prospectus dated 31 October 2020 (the “**RHP**”) with the Registrar of Companies, Telangana at Hyderabad, India (the “**RoC**”). The electronic form through which the RHP was filed with the RoC was registered with the RoC. Subsequently, on 2 November 2020, the RHP has been filed with SEBI, BSE and NSE. The RHP is available for viewing and downloading on the websites of BSE (www.bseindia.com), NSE (www.nseindia.com), SEBI (www.sebi.gov.in) and the relevant book running lead managers to Gland Pharma in relation to the Proposed Spin-Off and Separate Listing.

Shareholders and potential investors of Fosun Pharma and/or Fosun International should be aware that the RHP does not contain complete particulars of the price per Equity Share and size of the offering.

Further announcements will be made by Fosun Pharma and/or Fosun International in respect of the Proposed Spin-off and Separate Listing as and when appropriate.

Shareholders and potential investors of Fosun Pharma and/or Fosun International are advised to note that the Proposed Spin-off and Separate Listing is subject to, among other things, receipt of minimum subscription as set out in the RHP, the final listing and trading approvals from BSE and NSE and other factors. Accordingly, shareholders and potential investors of Fosun Pharma and/or Fosun International should be aware that there is no assurance that the Proposed Spin-off and Separate Listing will be successfully completed. Shareholders and potential investors of Fosun Pharma and/or Fosun International should therefore exercise caution when dealing in the securities of Fosun Pharma and/or Fosun International. Any person who is in doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional advisers.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

By order of the Board

Fosun International Limited

Guo Guangchang

Chairman

3 November 2020

As at the date of this announcement, the executive director of Fosun Pharma is Mr. Wu Yifang; the non-executive directors of Fosun Pharma are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of Fosun Pharma are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

As at the date of this announcement, the executive directors of Fosun International are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Qin Xuetao and Mr. Gong Ping; the non-executive directors of Fosun International are Ms. Chen Shucui and Mr. Zhuang Yuemin; and the independent non-executive directors of Fosun International are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang and Dr. Lee Kai-Fu.

* for identification purposes only